Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
0.9230
+0.0130 (1.43%)
At close: Apr 10, 2026

BCLI Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.787.0410.6910.879.3
Research & Development
4.184.6510.7513.9615.24
Operating Expenses
9.9511.6921.4424.8224.54
Operating Income
-9.95-11.69-21.44-24.82-24.54
Interest Expense
-0.53-0.08-0.28--
Interest & Investment Income
---0.550.08
Other Non Operating Income (Expenses)
0.180.154.53--
Pretax Income
-10.31-11.62-17.19-24.28-24.46
Net Income
-10.31-11.62-17.19-24.28-24.46
Net Income to Common
-10.31-11.62-17.19-24.28-24.46
Shares Outstanding (Basic)
95322
Shares Outstanding (Diluted)
95322
Shares Change (YoY)
84.58%74.87%17.99%0.91%21.22%
EPS (Basic)
-1.11-2.31-5.99-9.97-10.14
EPS (Diluted)
-1.11-2.31-5.99-9.97-10.20
Free Cash Flow
-6.98-9.09-20.48-19.35-26.6
Free Cash Flow Per Share
-0.75-1.81-7.13-7.95-11.03
EBITDA
-9.75-11.45-21.17-24.54-24.28
D&A For EBITDA
0.20.240.270.290.26
EBIT
-9.95-11.69-21.44-24.82-24.54
Source: S&P Global Market Intelligence. Standard template. Financial Sources.